Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death

AIDS

Volumn 25, Issue 4, 2011, Pages 441-451

  Kaufmann, Gilbert R ^a   Elzi, Luigia ^a   Weber, Rainer ^b   Furrer, Hansjakob ^c   Giulieri, Stefano ^d   Vernazza, Pietro ^e   Bernasconi, Enos ^f   Hirschel, Bernard ^g   Battegay, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

CD4 T cells; combination antiretroviral therapy; HIV infection; immunological recovery; interruptions

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; RISK FACTORS; TIME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 79951517916     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283430013     Document Type: Conference Paper

References (36)

1. Vo TT, Ledergerber B, Keiser O, Hirschel B, Furrer H, Battegay M, et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197:1685-1694. (Pubitemid 351919632)
2. Hammer S, Eron J, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection. JAMA 2008; 300:555-570.
3. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
4. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
5. Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, et al. CD4R T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008; 47:1093-1101.
6. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination anti-retroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170:57-65.
7. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15:413-423.
8. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465. (Pubitemid 44142768)
9. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
10. Swiss HIV Cohort Study. Cohort profile: the Swiss HIV Cohort Study. Int J Epidemiol 2010; 39:1179-1189.
11. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989. (Pubitemid 43867699)
12. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350-361.
13. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195. (Pubitemid 37248783)
14. JulgB, Walker BD. The paradoxofincomplete CD4R cell count restoration despite successful antiretroviral treatment and the need to start highly active antiretroviral therapy early. Clin Infect Dis 2009; 48:795-797.
15. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4R cell count restoration in HIV-infected patients receiving long-term anti-retroviral treatment. Clin Infect Dis 2009; 48:787-794.
16. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-1866.
17. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to (Pubitemid 41022115)
18. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G. The absence of CD4R T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328-337.
19. Haynes L, Maue AC. Effects of aging on T cell function. Curr Opin Immunol 2009; 21:414-417.
20. Cohen Stuart JW, Slieker WA, Rijkers GT, Noest A, Boucher CA, Suur MH, et al. Early recovery of CD4R T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. AIDS 1998; 12:2155-2159. (Pubitemid 28495269)
21. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Age, thymopoiesis, and CD4R T-lympho-cyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143-149.
22. Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749-1756. (Pubitemid 32939234)
23. Lecossier D, Bouchonnet F, Schneider P, Clavel F, Hance AJ. Discordant increases in CD4R T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001; 183:1009-1016. (Pubitemid 32230947)
24. Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brench-ley J, Fox C, et al. Evaluation of the pathogenesis of decreasing CD4(R)Tcell countsinhuman immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretro-viral therapy. J Infect Dis 2009; 199:1648-1656.
25. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-1736. (Pubitemid 44299364)
26. Estes J, Baker JV, Brenchley JM, Khoruts A, Barthold JL, Bantle A, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456-464.
27. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4R T-cell changes independent of viral load. Blood 2004; 104:942-947; Epub 2004 Apr 2029. (Pubitemid 39038012)
28. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543; Epub 2003 Apr 1523. (Pubitemid 36578959)
29. Benito JM, Lopez M, Lozano S, Ballesteros C, Martinez P, González-Lahoz J, Soriano V. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4R T cells under successful highly active anti-retroviral therapy. J Acquir Immune Defic Syndr 2005; 38:373-381. (Pubitemid 40381546)
30. Benito JM, Lopez M, Lozano S, Gonzalez-Lahoz J, Soriano V. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(R) cells after antiretro-viral therapy. J Infect Dis 2008; 198:1466-1473.
31. Kuller LH, TracyR,BellosoW,DeWitS,DrummondF,Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLOS Med 2008; 5:1496-1508.
32. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4R counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007; 44:179-187. (Pubitemid 46292221)
33. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-2418.
34. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
35. Bozzette SA, Ake CF, Tam HK, Phippard A, Cohen D, Scharfstein DO, Louis TA. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:338-341. (Pubitemid 351619420)
36. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. Mortality in the highly active anti-retroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)